Forschungsbericht 2002/2003 - Medizinische Klinik 1 - Friedrich ...

Behandlungscharakteristika, die den Behandlungserfolg vorhersagen lassen und zur Optimierung der
Therapieergebnisse beitragen. Der Piezolith 3000 wird im Rahmen des Medizinproduktegesetztes bei
Patienten mit Gallengangs-, Gallenblasen- und Prankreaskonkrementen evaluiert (Dr. Benninger,
Dr. Rabenstein, Dr. Schaber).
Clinical and Experimental Hepatology (Hepatitis, Oncology, Fibrogenesis and Fibrolysis,
Lithotripsy)
Hepatitis C, the treatment of biliary and pancreatic stone disease by shock waves, primary liver cell
carcinoma, alcoholic liver disease and the development and dissolution of liver fibrosis are
investigated on the level of molecular biology, biochemistry, cell biology, and clinical investigations
(see list of published papers for an overview).
Kooperationen
- Dr. A. Casini, Dept. of Clinical Pathophysiology, Univ. of Florence, Florenz, Italien.
- Dr. J.C. Dent/Dr. F. Gray, Glaxo Hepatitis Res., Greenford, UK.
- Prof. R. dePinho, Dept. of Mol. Biol., Harvard Med. School, Boston, USA
- Dr. J.D. Jia, Capital Institute of Medicine, Beijing Friendship Hospital, Beijing, VR China.
- Prof. A. Geerts, Institute for Cell Biology, Univ. of Newcastle upon Tine, UK.
- Prof. G.R. Martin, Fibrogene, South San Francisco, CA, USA.
- Prof. T. Nakamura, Div. of Biochemistry, Osaka Univ. School of Medicine, Osaka, Japan.
- Dr. T. Niki, Dept. of Biotechnology, Univ. of Tokio, Japan.
- Prof. M. Pinzani, Dept. of Internal Medicine I, Univ. of Florence, Italien.
- Dr. K. Poelstra, Prof. D. Meijer, Dept. of Pharmacology and drug targeting, Groningen, NL
- Dr. S. Reif, Dept. of Pediatric Gastroenterology, Univ. of Tel-Aviv, Israel
- Dr. K. Rombouts, Institute for Cell Biology, Free Univ. of Brussels, Belgien
- Prof. H. Tilg, Dept. of Gastroenterology and Hepatology, Univ. Innsbruck, Österreich
- Prof. B.E.Wang, Institute of Medicine, Beijing Friendship Hospital, Beijing, VR China.
Finanzierung/Funding
Begutachtete Drittmittel
32